Rebang Pharmaceutical-B announced that the company's AP306 global phase IIb multi-regional clinical trial for treating hyperphosphatemia in patients undergoing maintenance hemodialysis has completed the first randomized enrollment and administration of subjects. The trial is being carried out at various clinical centers in the US and China. It is planned to recruit about 168 participants. The main findings are expected to be announced in the first half of 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.